| 1 | strongly | 6,314 |
| 2 | weakly | 620 |
| 3 | powerfully | 31 |
| 4 | lent | 17 |
| 5 | anti-myelin | 11 |
| 6 | 'strongly | 6 |
| 7 | lysosphingolipid | 4 |
| 8 | biomimetically | 3 |
| 9 | cementoblasts | 3 |
| 10 | anti-ro/ss-a | 2 |
| 11 | bio-medically | 2 |
| 12 | cin1+/cin2+/cin3+ | 2 |
| 13 | gcs/ggs | 2 |
| 14 | replicably | 2 |
| 15 | 'empirically | 1 |
| 16 | 1,8-dihydroxy | 1 |
| 17 | 101.6°f | 1 |
| 18 | 1910-1960 | 1 |
| 19 | 5,735 | 1 |
| 20 | 5-is | 1 |
| 21 | adolescent-appropriate | 1 |
| 22 | adv- | 1 |
| 23 | anxio-selectivity | 1 |
| 24 | assay/organism | 1 |
| 25 | cardiovascular-pain | 1 |
| 26 | clinic-was | 1 |
| 27 | codominantly | 1 |
| 28 | connection-distance | 1 |
| 29 | deficiently | 1 |
| 30 | dinoflagellete | 1 |
| 31 | estrogen-dose | 1 |
| 32 | fmd-change | 1 |
| 33 | frequently-those | 1 |
| 34 | ganglionopathy | 1 |
| 35 | genes/microrna | 1 |
| 36 | heating-rate | 1 |
| 37 | heterogeneous.we | 1 |
| 38 | instructional/emotional | 1 |
| 39 | intially | 1 |
| 40 | lipid-load | 1 |
| 41 | low-intensity/dose | 1 |
| 42 | misdiagnosised | 1 |
| 43 | model-that | 1 |
| 44 | non-length | 1 |
| 45 | non-ls | 1 |
| 46 | overdistensibility | 1 |
| 47 | p4-atpase | 1 |
| 48 | participation/retention | 1 |
| 49 | particulaly | 1 |
| 50 | pdt-srp | 1 |
| 51 | phenotype-specifically | 1 |
| 52 | phospho-dephosphorylation | 1 |
| 53 | phylogeographically | 1 |
| 54 | poignantly | 1 |
| 55 | procedural-that | 1 |
| 56 | protein-load | 1 |
| 57 | pyridine/pyrimidine/pyrazine | 1 |
| 58 | r12-type | 1 |
| 59 | risk.we | 1 |
| 60 | ros-os | 1 |
| 61 | salubriously | 1 |
| 62 | susceptible-dose | 1 |
| 63 | t1/2/m | 1 |
| 64 | tcgv | 1 |
| 65 | thermoclines | 1 |
| 66 | tumor-angiogenesis | 1 |
| 1 | 'empirically | 1 |
| 2 | 'strongly | 6 |
| 3 | 1,8-dihydroxy | 1 |
| 4 | 101.6°f | 1 |
| 5 | 1910-1960 | 1 |
| 6 | 5,735 | 1 |
| 7 | 5-is | 1 |
| 8 | adolescent-appropriate | 1 |
| 9 | adv- | 1 |
| 10 | anti-myelin | 11 |
| 11 | anti-ro/ss-a | 2 |
| 12 | anxio-selectivity | 1 |
| 13 | assay/organism | 1 |
| 14 | bio-medically | 2 |
| 15 | biomimetically | 3 |
| 16 | cardiovascular-pain | 1 |
| 17 | cementoblasts | 3 |
| 18 | cin1+/cin2+/cin3+ | 2 |
| 19 | clinic-was | 1 |
| 20 | codominantly | 1 |
| 21 | connection-distance | 1 |
| 22 | deficiently | 1 |
| 23 | dinoflagellete | 1 |
| 24 | estrogen-dose | 1 |
| 25 | fmd-change | 1 |
| 26 | frequently-those | 1 |
| 27 | ganglionopathy | 1 |
| 28 | gcs/ggs | 2 |
| 29 | genes/microrna | 1 |
| 30 | heating-rate | 1 |
| 31 | heterogeneous.we | 1 |
| 32 | instructional/emotional | 1 |
| 33 | intially | 1 |
| 34 | lent | 17 |
| 35 | lipid-load | 1 |
| 36 | low-intensity/dose | 1 |
| 37 | lysosphingolipid | 4 |
| 38 | misdiagnosised | 1 |
| 39 | model-that | 1 |
| 40 | non-length | 1 |
| 41 | non-ls | 1 |
| 42 | overdistensibility | 1 |
| 43 | p4-atpase | 1 |
| 44 | participation/retention | 1 |
| 45 | particulaly | 1 |
| 46 | pdt-srp | 1 |
| 47 | phenotype-specifically | 1 |
| 48 | phospho-dephosphorylation | 1 |
| 49 | phylogeographically | 1 |
| 50 | poignantly | 1 |
| 51 | powerfully | 31 |
| 52 | procedural-that | 1 |
| 53 | protein-load | 1 |
| 54 | pyridine/pyrimidine/pyrazine | 1 |
| 55 | r12-type | 1 |
| 56 | replicably | 2 |
| 57 | risk.we | 1 |
| 58 | ros-os | 1 |
| 59 | salubriously | 1 |
| 60 | strongly | 6,314 |
| 61 | susceptible-dose | 1 |
| 62 | t1/2/m | 1 |
| 63 | tcgv | 1 |
| 64 | thermoclines | 1 |
| 65 | tumor-angiogenesis | 1 |
| 66 | weakly | 620 |
| 1 | cin1+/cin2+/cin3+ | 2 |
| 2 | adv- | 1 |
| 3 | 1910-1960 | 1 |
| 4 | 5,735 | 1 |
| 5 | anti-ro/ss-a | 2 |
| 6 | genes/microrna | 1 |
| 7 | lipid-load | 1 |
| 8 | protein-load | 1 |
| 9 | misdiagnosised | 1 |
| 10 | lysosphingolipid | 4 |
| 11 | connection-distance | 1 |
| 12 | fmd-change | 1 |
| 13 | pyridine/pyrimidine/pyrazine | 1 |
| 14 | r12-type | 1 |
| 15 | p4-atpase | 1 |
| 16 | susceptible-dose | 1 |
| 17 | estrogen-dose | 1 |
| 18 | low-intensity/dose | 1 |
| 19 | frequently-those | 1 |
| 20 | adolescent-appropriate | 1 |
| 21 | heating-rate | 1 |
| 22 | dinoflagellete | 1 |
| 23 | risk.we | 1 |
| 24 | heterogeneous.we | 1 |
| 25 | 101.6°f | 1 |
| 26 | non-length | 1 |
| 27 | instructional/emotional | 1 |
| 28 | t1/2/m | 1 |
| 29 | assay/organism | 1 |
| 30 | cardiovascular-pain | 1 |
| 31 | anti-myelin | 11 |
| 32 | phospho-dephosphorylation | 1 |
| 33 | participation/retention | 1 |
| 34 | pdt-srp | 1 |
| 35 | clinic-was | 1 |
| 36 | thermoclines | 1 |
| 37 | gcs/ggs | 2 |
| 38 | 5-is | 1 |
| 39 | tumor-angiogenesis | 1 |
| 40 | non-ls | 1 |
| 41 | ros-os | 1 |
| 42 | cementoblasts | 3 |
| 43 | procedural-that | 1 |
| 44 | model-that | 1 |
| 45 | lent | 17 |
| 46 | tcgv | 1 |
| 47 | ganglionopathy | 1 |
| 48 | particulaly | 1 |
| 49 | replicably | 2 |
| 50 | strongly | 6,314 |
| 51 | 'strongly | 6 |
| 52 | weakly | 620 |
| 53 | bio-medically | 2 |
| 54 | phenotype-specifically | 1 |
| 55 | phylogeographically | 1 |
| 56 | 'empirically | 1 |
| 57 | biomimetically | 3 |
| 58 | intially | 1 |
| 59 | powerfully | 31 |
| 60 | salubriously | 1 |
| 61 | poignantly | 1 |
| 62 | codominantly | 1 |
| 63 | deficiently | 1 |
| 64 | overdistensibility | 1 |
| 65 | anxio-selectivity | 1 |
| 66 | 1,8-dihydroxy | 1 |